BALPHARMA

Bal Pharma Ltd.

NSE: BALPHARMA

BSE: 524824

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

83.57-2.3 (-2.70%)

26 Aug, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

45.3 / 100

Value Score

84.3 / 100

Price Momentum Score

63.6 / 100

QVM Score

78.4 / 100

Key Metrics

Market Cap

133.05

P/E (TTM)

21.87

P/B

1.62

P/S (TTM)

0.40

EV/EBITDA

8.33

CAPE (5Y)

23.21

ROE (TTM)

7.87

ROCE (TTM)

8.87

ROA (TTM)

1.77

Avg 3Y ROE

9.61

Earnings 3Y CAGR

46.67

Sales 3Y CAGR

3.19

Sales 5Y CAGR

4.46

Debt/Equity

1.94

Consensus TP

Strong Buy %

Promoter Holding

50.86

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Bal Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Stock is reasonably valued and PE TTM is at a discount to industry median

PE TTM of 21.87 indicates that the stock is reasonably valued on a standalone basis. Discount to industry median P/E is decent at -28.41%

What is P/E Ratio?

Median: 30.55

Value 21.87

-0.99726.77

Moderate revenue growth and above median growth of industry

The company delivered moderate revenue growth of 13.66% for 12-month ended 30 Jun 2026 and the growth was 3.07 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value 13.66

-99.6111701.8

Consistently pays dividend

The company has not missed dividend payments once in the last 5 financial years

What is Dividend streak?

Negative

Low and declining ROE

The company reported low ROE of 7.87% for 12-month ended 30 Jun 2026 and ROE declined by -197 bps from 1 year ago

What is ROE (FY)?

Low but stable operating margin

The company reported low operating margin of 6.68% for 12-month ended 30 Jun 2026 and operating margin improved marginally by 12 bps from 1 year ago

What is Operating profit margin?

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of 3.17% for 12-month ended 30 Jun 2026 and the growth was 4.03 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Neutral

Reasonable Debt to Equity, and has been stable

The company has reasonable Debt to Equity of 1.94 as on 30 Jun 2026 and Debt to Equity remained same in the last 1 year

What is Debt to Equity?

Company's earnings are of moderate quality

Earnings quality score of 68.3 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

68.3 / 100

Moderate dividend yield

The company has a moderate dividend yield of 1.44%

What is Dividend yield?

Financial Snapshot

See detailed analysis

Multi-year trends for Bal Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Bal Pharma Ltd. Shareholding Pattern

Quarterly breakdown of Bal Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	42.45	42.45	42.45	42.45	44.98	44.84	46.87	49.57	49.57	52.00	52.00	51.61	51.61	51.61	51.61	51.23	51.23	51.23	50.86	50.86	50.86	50.86	50.86	50.86	50.86	50.86
Indian Promoter	37.83	37.83	37.83	37.83	40.56	40.42	42.45	45.15	45.15	47.79	47.79	47.43	47.43	47.43	47.43	47.09	47.09	47.09	46.74	46.74	46.74	46.74	46.74	46.74	46.74	46.74
Foreign Promoter	4.62	4.62	4.62	4.62	4.42	4.42	4.42	4.42	4.42	4.21	4.21	4.18	4.18	4.18	4.18	4.15	4.15	4.15	4.12	4.12	4.12	4.12	4.12	4.12	4.12	4.12
Institutions	0.02	0.02	0.01	-	-	-	0.15	0.31	0.31	0.30	0.20	0.18	0.17	0.17	0.14	0.13	0.13	0.13	0.13	0.14	0.14	0.15	0.22	0.14	0.14	0.15
Mutual Funds / UTI	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.02	0.02	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.15	0.31	0.31	0.30	0.20	0.18	0.17	0.17	0.14	0.13	0.13	0.13	0.13	0.14	0.14	0.15	0.23	0.14	0.14	0.15
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Institution	57.53	57.53	57.53	57.55	55.02	55.16	52.98	50.12	50.12	47.71	47.80	48.21	48.23	48.23	48.25	48.64	48.64	48.64	49.01	49.00	49.00	48.99	48.92	49.01	49.01	48.99
Bodies Corporate	1.23	1.26	0.83	0.73	0.77	0.67	0.89	0.61	0.54	-	0.64	0.50	0.46	0.36	0.37	0.40	0.52	0.48	0.71	0.82	0.77	0.77	0.42	0.39	0.50	0.55
Others (incl. Retail) No. of shareholders	56.30 11,251	56.27 11,956	56.70 12,303	56.82 12,600	54.25 12,569	54.49 16,458	52.09 16,236	49.51 15,975	49.58 16,154	47.71 16,305	47.16 16,096	47.71 16,396	47.77 15,967	47.87 15,801	47.88 15,469	48.24 15,000	48.12 14,709	48.16 14,954	48.30 15,926	48.18 15,585	48.23 15,647	48.22 15,749	48.50 15,710	48.62 15,462	48.51 15,158	48.44 14,913

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Bal Pharma Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
SHAILESH SIROYA Promoter & Director	April-2022	Preferential Offer (Acquisition) 13th Apr 2022	13.46 %	₹ 50.00	7.50 lac	₹ 3.75 cr
MICRO LABS LIMITED Promoter	December-2021	Market Purchase (Acquisition) 21st Dec 2021	8.84 %	₹ 23.24	12.04 lac	₹ 2.80 cr
MICRO LABS LIMITED Promoter	November-2021	Market Purchase (Acquisition) 24th Nov 2021	10.87 %	₹ 92.45	4.00 lac	₹ 3.70 cr
SHAILESH SIROYA Promoter	March-2021	Conversion of security (Acquisition) 22nd Mar 2021	9.49 %	₹ 50.00	6.50 lac	₹ 3.25 cr

Corporate Actions

History of Bal Pharma Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 1.20/share
Record date: 18th Sep 2025Ex-date: 18th Sep 2025
Announced on: 29th May 2025
Dividend₹ 1.20/share
Record date: 18th Sep 2024Ex-date: 17th Sep 2024
Announced on: 28th May 2024
Dividend₹ 1/share
Record date: 18th Sep 2023Ex-date: 18th Sep 2023
Announced on: 29th May 2023
Dividend₹ 1/share
Record date: 14th Sep 2022Ex-date: 13th Sep 2022
Announced on: 30th May 2022
Dividend₹ 1/share
Record date: 17th Sep 2021Ex-date: 16th Sep 2021
Announced on: 29th Jun 2021

Company Profile

Overview of Bal Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Bal Pharma Limited is a pharmaceutical company engaged in the manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It specializes in prescription drugs, generic & OT...

Key personnel

Mr. Akash Mathur

Chief Executive Officer

Mr. Shreepada M. L.

Compliance Officer, Company Secretary

Shailesh D. SiroyaD

Managing Director, Executive Director

Sarika BhandariD

Additional Director

Mr. Ravindra Kumar KothariD

Non-Independent Non-Executive Director

Mr. Jatish ShethD

Additional Non-Executive Director

Ms. Nicola NeeladriD

Independent Director

Incorporated on

19 May 1987

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

IPO date

01 Feb 1995

Free Float

55,27,847

Website

https://www.balpharma.com/

Phone no.

+918041379500

Address

5th Floor Lakshmi Narayan Complex 10/1 Palace Road Bengaluru, Chickpet, , 560053, India

Frequently Asked Questions

What is the current share price of Bal Pharma Ltd.?

The current share price of Bal Pharma Ltd. is ₹ 83.57 as of 26 Aug 2026.

What is the market capitalisation of Bal Pharma Ltd.?

The market capitalisation of Bal Pharma Ltd. stands at ₹ 133.05 Cr.

What is the PE ratio of Bal Pharma Ltd.?

The Price-to-Earnings (PE) ratio of Bal Pharma Ltd. is 21.87 as of the latest trailing twelve months data.

What is the ROE and ROCE of Bal Pharma Ltd.?

Bal Pharma Ltd. has a Return on Equity (ROE) of 7.87% and a Return on Capital Employed (ROCE) of 8.87% as per the latest financial reports.

What is the 52-week high and low of Bal Pharma Ltd.?

The 52-week high of Bal Pharma Ltd. is - and the 52-week low is -.

What is the dividend yield of Bal Pharma Ltd.?

The dividend yield of Bal Pharma Ltd. is 1.44% based on the current market price.

What is the FII and DII holding in Bal Pharma Ltd.?

Foreign Institutional Investors (FII) hold 0.15%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 48.44% of Bal Pharma Ltd. shares.

What sector does Bal Pharma Ltd. belong to?

Bal Pharma Ltd. operates in the Healthcare sector.

What is the beta of Bal Pharma Ltd.?

The beta of Bal Pharma Ltd. is 0.89, indicating its price volatility relative to the broader market. Over the past 1 year, Bal Pharma Ltd. has delivered an absolute return of -8.33%.

What is the RSI of Bal Pharma Ltd.?

The 14-day Relative Strength Index (RSI) of Bal Pharma Ltd. is 42.91, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Bal Pharma Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Bal Pharma Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Company Profile

Corporate Actions

Stock Analysis